Navigation Links
Biomarker associated with poor outcome in aggressive childhood cancer
Date:4/6/2009

Results from a new study identify a biomarker that may be useful for predicting the outcome of treatment for neuroblastoma, the most common cancer in young children. The research, published by Cell Press in the April 7th issue of the journal Cancer Cell, also provides new information about the molecular signals that are involved in the progression of this often devastating pediatric cancer.

Retinoic acid (RA) is a metabolite of Vitamin A that has important influences over the processes of growth and differentiation. RA mediates gene expression by interacting with retinoic acid receptors (RARs) that, in the presence of RA, switch from repressing target genes to activating them. Because many targets of RA induce differentiation or cell death, RA is used as a therapeutic agent in many cancers, including neuroblastoma.

"Many neuroblastoma patients exhibit aggressive tumors with poor clinical outcome," explains senior study author Dr. Rene Bernards from The Netherlands Cancer Institute. "While some of these aggressive tumors exhibit increased expression of the MYCN oncogene, little is known about the other genetic factors that control neuroblastoma progression." Dr. Bernards and colleagues performed a genome-wide RNA interference screen to search for additional components of the RA signaling pathway that might be linked to neuroblastoma.

The researchers identified ZNF423 as a critical cofactor of RA-induced differentiation. Reduced expression of ZNF423 was led to a growth advantage and resistance to RA differentiation in neuroblastoma cells while increased expression of ZNF423 led to growth inhibition and enhanced differentiation. The researchers went on to show that ZNF423 interacts with the RAR?/RXR? nuclear receptor that is necessary for activation in response to retinoids.

Importantly, low expression levels of ZNF423 were associated with poor disease outcome in neuroblastoma patients, suggesting that the gene might be useful as a prognostic biomarker. "Expression levels of ZNF423 could significantly affect responses to both endogenous and pharmacological concentrations of RA in cancer patients, which may in turn influence the outcome of neuroblastoma," offers Dr. Bernards. "Therefore, ZNF423 may be a useful biomarker for predicting responses to RA-based therapies, which are increasingly being used to treat neuroblastoma."


'/>"/>

Contact: Cathleen Genova
cgenova@cell.com
617-397-2802
Cell Press
Source:Eurekalert

Related medicine news :

1. Naturally fluorescent molecules may serve as cancer biomarker
2. Wayne State University Scientists ID New Biomarker for Prostate Cancer
3. Scientists ID New Biomarker for Prostate Cancer
4. Penn Medicine pathologists pioneer biomarker test to diagnose or rule out Alzheimers disease
5. Dr. Arun Sreekumar lectures on new candidate biomarker at Annual EAU Congress
6. Biomarkers detected for Chikungunya fever
7. Biomarker predicts disease recurrence in colorectal cancer
8. Major study on DiagnoCures GCC biomarker published in Jama
9. Researchers ID Biomarker for Fatal Prostate Cancer
10. Biomarker Combination and Risk of Ovarian Malignancy Algorithm (Roma(TM)) Demonstrates Accuracy in Detecting Ovarian Cancer
11. MDS Analytical Technologies Laser Capture Microdissection Helps Facilitate Discovery of Potential New Colon-Cancer Biomarker
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... , ... Dr. Alan I. Benvenisty, MD is dual board certified in general ... for his distinguished expertise and experience in the diagnosis and treatment of vascular diseases. ... renovascular disease and aortic aneurysm . He is known for his minimally invasive ...
(Date:5/24/2017)... (PRWEB) , ... May 24, 2017 , ... Dr. Manju ... comfortable ClearCorrect orthodontics, with or without a referral. Dr. Kejriwal understands the ... she offers convenient, clear braces in Cincinnati, OH. Patients no longer need to feel ...
(Date:5/24/2017)... ... May 24, 2017 , ... Dr. ... of the HP3 (High-Performance Periodontal Practice) continuing education (CE) series. As a compassionate ... in his field by attending numerous CE courses each year. His recent course, ...
(Date:5/24/2017)... , ... May 24, 2017 , ... If you are thinking of a visit to ... in business architecture, October is the perfect time to visit. , Business Architecture Associates is ... la carte offering for individuals, as a 4-½ day package for individuals, and as 4-½ ...
(Date:5/24/2017)... ... May 24, 2017 , ... Fiberstar, ... solutions for the food and beverage industry offers Citri-Fi®, a natural citrus fiber, ... the purchasing decision process. As a result, labels need to deliver simple, transparent ...
Breaking Medicine News(10 mins):
(Date:5/9/2017)... , May 9, 2017  Oramed Pharmaceuticals Inc. ... a clinical-stage pharmaceutical company focused on the development ... the Canadian Intellectual Property Office has granted Oramed ... Administration of Exenatide". The patent covers Oramed,s invention ... GLP-1 is an incretin hormone that stimulates ...
(Date:5/6/2017)... , May 5, 2017  May is Stroke Awareness ... of the most important methods to prevent a stroke: ... Centers for Disease Control and Prevention, undetected and uncontrolled ... Omron, the global leader in personal heart health ... elimination of heart attack and stroke and is advancing ...
(Date:5/4/2017)... LAWRENCE, Mass. and SAN DIEGO ... of Obstetricians and Gynecologists (ACOG) 2017 Annual Clinical and ... of single-use, self-contained, illuminating medical devices, today announced the ... size of its OfficeSPEC and ER-SPEC ... large, the addition of extra-small and extra-large sizes makes ...
Breaking Medicine Technology: